SCHEMBL3615906

SCHEMBL3615906

Cc1[nH]c(-c2ccnc(Cl)c2)cc1C#N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.42
ROCK2 O75116 1/20 0.42
MAP4K4 O95819 1/20 0.42
CDK2 P24941 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
GSK3B P49841 1/20 0.42
HIPK2 Q9H2X6 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
KDM4E B2RXH2 2/20 0.40
PDE3B Q13370 2/20 0.40
PDE3A Q14432 2/20 0.40
PDE5A O76074 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
PTGS1 P23219 1/20 0.40
PDE4A P27815 1/20 0.40
CYP2C19 P33261 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13442731 0.85 CDC7 (0.42) CDC7ROCK2MAP4K4CDK2MAPKAPK2
SCHEMBL3616057 0.82 CDC7 (0.40) CDC7ROCK2MAP4K4CDK2MAPKAPK2
SCHEMBL3618292 0.76 MAPKAPK2 (0.53) MAPKAPK2GSK3BKDM4EMAPTKMT2A
SCHEMBL3618285 0.76 ROCK2 (0.40) CDC7ROCK2MAP4K4CDK2MAPKAPK2
SCHEMBL5744620 0.76 KDM4E (0.48) KDM4ELMNAHPGDIDO1LRRK2
SCHEMBL3609410 0.74 CDK9 (0.49) CDC7ROCK2MAP4K4CDK2MAPKAPK2
Hydrochloric Acid SCHEMBL3617474 0.73 CDK9 (0.48) CDC7ROCK2MAP4K4CDK2MAPKAPK2
SCHEMBL3618175 0.73 TBK1 (0.45) ROCK2KDM4EMAPK1LRRK2
SCHEMBL3609053 0.72 MAPKAPK2 (0.53) CDC7ROCK2CDK2MAPKAPK2GSK3B
SCHEMBL3609049 0.72 MAPKAPK2 (0.53) CDC7ROCK2CDK2MAPKAPK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105664-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-29 US disclosed
US-20100105664-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-29 US disclosed
US-20100105664-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-29 US disclosed
EP-2069333-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES Novartis Ag (CH) 2009-06-17 EP disclosed
WO-2008034600-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES NOVARTIS AG (CH) 2008-03-27 WO disclosed
WO-2008034600-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES NOVARTIS AG (CH) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105664-A1 ORGANIC COMPOUNDS SLCO1B3, SLCO1B1, SLC10A6 CDC7 4089/4885ROCK2 3665/4885MAP4K4 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.